This is a chimeric IgG1 monoclonal antibody using the same sequences as the therapeutic antibody infliximab. It functions as a potent tumor necrosis factor alpha (TNFa) antagonist. TNFa is a crucial proinflammatory cytokine involved in chronic inflammatory diseases. The hyperactivity and enhanced signalling pathways of TNFa can be observed in the diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNFa, infliximab disrupts the interaction between TNFa and its receptors and may also induce lysis of TNFa-producing cells. Its inhibitory effects have been demonstrated in human fibroblasts, endothelial cells, neutrophils, B and T lymphocytes, as well as epithelial cells. Additionally, infliximab atteunates the synthesis of tissue-degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab is indicated for treating various autoimmune diseases including adult or pediatric Crohn’s disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis.